+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Thyroid Cancer Drugs Global Market Report 2020

  • ID: 4871565
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Abbott laboratories
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bionomics
  • Biovista
  • Eisai
  • MORE
Thyroid Cancer Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global thyroid cancer drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the thyroid cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Thyroid Cancer Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Others 2) By End Users: Hospitals, Oncology Clinics, Research Organizations, Others 3) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Others
  • Companies Mentioned: Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co., Teva parenteral medicines Inc., Jerome Stevens Pharmaceuticals Inc.
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott laboratories
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bionomics
  • Biovista
  • Eisai
  • MORE
1. Executive Summary

2. Thyroid Cancer Drugs Market Characteristics

3. Thyroid Cancer Drugs Market Size And Growth
3.1. Global Thyroid Cancer Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Thyroid Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Thyroid Cancer Drugs Market Segmentation
4.1. Global Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Ipilimumab
  • Cabozantinib-S-Malate
  • Caprelsa (Vandetanib)
  • Doxorubicin Hydrochloride
  • Lenvatinib Mesylate
  • Nivolumab
  • Vandetanib
  • Others
4.2. Global Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hospitals
  • Oncology Clinics
  • Research Organizations
  • Others
4.3. Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Radioiodine Ablation
  • Thyroid Stimulating Hormone (THS) Suppression
  • Chemotherapy
  • Targeted Multikinase Therapy
  • Others
5. Thyroid Cancer Drugs Market Regional And Country Analysis
5.1. Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Thyroid Cancer Drugs Market
6.1. Asia-Pacific Thyroid Cancer Drugs Market Overview
6.2. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.4. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Thyroid Cancer Drugs Market
7.1. China Thyroid Cancer Drugs Market Overview
7.2. China Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.4. China Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Thyroid Cancer Drugs Market
8.1. India Thyroid Cancer Drugs Market Overview
8.2. India Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.4. India Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Thyroid Cancer Drugs Market
9.1. Japan Thyroid Cancer Drugs Market Overview
9.2. Japan Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.4. Japan Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Thyroid Cancer Drugs Market
10.1. Australia Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.3. Australia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Thyroid Cancer Drugs Market
11.1. Indonesia Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.3. Indonesia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Thyroid Cancer Drugs Market
12.1. South Korea Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.3. South Korea Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Thyroid Cancer Drugs Market
13.1. Western Europe Thyroid Cancer Drugs Market Overview
13.2. Western Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.4. Western Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Thyroid Cancer Drugs Market
14.1. UK Thyroid Cancer Drugs Market Overview
14.2. UK Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.4. UK Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Thyroid Cancer Drugs Market
15.1. Germany Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.3. Germany Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Thyroid Cancer Drugs Market
16.5. France Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.6. France Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.7. France Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Thyroid Cancer Drugs Market
17.1. Eastern Europe Thyroid Cancer Drugs Market Overview
17.2. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.4. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Thyroid Cancer Drugs Market
18.1. Russia Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.3. Russia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Thyroid Cancer Drugs Market
19.1. North America Thyroid Cancer Drugs Market Overview
19.2. North America Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.4. North America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Thyroid Cancer Drugs Market
20.1. USA Thyroid Cancer Drugs Market Overview
20.2. USA Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.4. USA Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Thyroid Cancer Drugs Market
21.1. South America Thyroid Cancer Drugs Market Overview
21.2. South America Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.4. South America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Thyroid Cancer Drugs Market
22.1. Brazil Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.3. Brazil Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Thyroid Cancer Drugs Market
23.1. Middle East Thyroid Cancer Drugs Market Overview
23.2. Middle East Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.4. Middle East Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Thyroid Cancer Drugs Market
24.1. Africa Thyroid Cancer Drugs Market Overview
24.2. Africa Thyroid Cancer Drugs Market, Segmentation By Drug Type:, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.4. Africa Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Thyroid Cancer Drugs Market Competitive Landscape And Company Profiles
25.1. Thyroid Cancer Drugs Market Competitive Landscape
25.2. Thyroid Cancer Drugs Market Company Profiles
25.2.1. Mylan Pharmaceuticals Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Alara Pharmaceutical Corporation
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Bristol Myers co.
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Teva parenteral medicines Inc.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Jerome Stevens Pharmaceuticals Inc.
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Thyroid Cancer Drugs Market

27. Thyroid Cancer Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Thyroid Cancer Drugs Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott laboratories
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bionomics
  • Biovista
  • Eisai
  • MORE
The thyroid cancer drugs market consists of sales of drugs that are used to treat thyroid cancer. The thyroid tissue is made up of follicular cells and parafollicular cells in which cancer develops. The types of thyroid cancer include follicular, papillary, medullary, anaplastic and thyroid lymphoma.

The global thyroid cancer drugs market was valued at about $0.4 billion in 2018 and is expected to grow to $0.77 billion at a CAGR of 17.7% through 2022.

North America was the largest region in the thyroid cancer drugs market in 2018, followed by Europe. The thyroid cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

Increasing incidences of thyroid cancer, especially in women is driving the thyroid cancer drugs market. According to the American Cancer Society, women are three times more likely to develop thyroid cancer than men. Thyroid cancer is rising at a fast pace and it is estimated that 52,070 new cases of thyroid cancer will be found in the USA in 2019 and an estimated 2,170 deaths will occur because of the disease. The increase in thyroid cancer can be attributed to exposure to radiation, family history of goiter and some hereditary syndromes.

Increasing use of targeted therapies for the treatment of thyroid cancer is acting as a restraint on the thyroid cancer drugs market. Targeted therapies target cancer specific genes, proteins and tissues that promote cancer growth and survival. Targeted therapies are increasingly being used to treat thyroid cancer as thyroid hormone-based treatments including radioactive iodine therapy are not effective against these cancers. For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC). As patients increasingly use targeted therapies for treatment, demand for thyroid cancer drugs is decreasing, affecting market growth.

Combination drugs are increasingly being used in the treatment of thyroid cancer as they are more effective and help prevent cancer progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance and prevent the growth of cancer cells. For instance, in 2018, the FDA approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for the treatment of anaplastic thyroid cancer.

Manufacturers of thyroid cancer drugs are governed by regulatory authorities such as the Food and Drug Administration in the USA. For instance, off-label usage of FDA approved drugs for the treatment of cancer requires approval from the FDA. Manufacturers are required to submit a supplemental marketing application called sNDA( Supplemental New Drug Application) to the FDA that approves the drug for prescription.

In February 2019, Eli Lilly and Company acquired Loxo Oncology, Inc.for $8 Billion. The acquisition provides Eli Lilly access to a pipeline of investigational medicines like RET inhibitors which are used in thyroid cancer treatment. Loxo Oncology was established in 2013 and is located in Stamford, USA.

Major players in the market are Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co., Teva parenteral medicines Inc., Jerome Stevens Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
5 of 5
  • Mylan Pharmaceuticals Inc.
  • Alara Pharmaceutical Corporation
  • Bristol Myers co.
  • Teva parenteral medicines Inc.
  • Jerome Stevens Pharmaceuticals Inc.
  • Baxter International Inc.
  • Abbott laboratories
  • App pharmaceuticals llc.
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Exelixis Inc.
  • Novartis AG
  • Pfizer Inc.
  • Biovista
  • Vascular Biogenics
  • Azaya Therapeutics
  • Bionomics
  • Bayer
  • Eisai
  • Bio-Path Holdings
  • Takeda Pharmaceutical Company
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll